Welcome to our dedicated page for Kyverna Therapeutics SEC filings (Ticker: KYTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kyverna Therapeutics is redefining autoimmune care with CD19-targeted CAR T cells, yet its SEC disclosures weave together trial endpoints, collaboration milestones, and dilution details that can bury critical signals. If you’ve ever searched dozens of PDFs for one R&D expense line or an FDA hold notice, you already know the pain.
Stock Titan removes that friction. Our AI reads every submission the second it hits EDGAR, then delivers Kyverna Therapeutics SEC filings explained simply. Drill into a Kyverna Therapeutics annual report 10-K simplified to see cash runway and pipeline updates, or open a Kyverna Therapeutics quarterly earnings report 10-Q filing for side-by-side trend analysis. Need real-time insider sentiment? We surface Kyverna Therapeutics insider trading Form 4 transactions and flag any Kyverna Therapeutics Form 4 insider transactions real-time. Material news is never missed—each Kyverna Therapeutics 8-K material events explained highlights clinical trial pauses, partnership payments, or equity offerings in plain language.
Professionals use the platform to:
- Track R&D spend vs. cash on hand through our Kyverna Therapeutics earnings report filing analysis.
- Monitor management incentives via Kyverna Therapeutics proxy statement executive compensation.
- Spot buying or selling trends with Kyverna Therapeutics executive stock transactions Form 4.
- Save hours by understanding Kyverna Therapeutics SEC documents with AI instead of wading through 250-page reports.
Whether you’re preparing a valuation model or checking compliance, Stock Titan’s AI-powered summaries, expert context, and real-time alerts make complex biotech filings effortless.
Kyverna Therapeutics, Inc. entered into an underwriting agreement for an underwritten public offering of 13,333,333 shares of common stock at a public offering price of $7.50 per share. Underwriters will purchase the shares at $7.05 per share and have a 30-day option to buy up to an additional 1,999,999 shares at the public offering price, less underwriting discounts and commissions.
The company expects gross proceeds of approximately $100 million, before deducting underwriting discounts, commissions and offering expenses. Kyverna intends to use the net proceeds for general corporate purposes, which may include funding research and development, capital expenditures, working capital and general and administrative expenses. Closing is expected on or about December 18, 2025, subject to customary conditions, and directors, executive officers and certain affiliated stockholders are subject to lock-up agreements generally through January 31, 2026.
Kyverna Therapeutics, Inc. is issuing 13,333,333 shares of common stock at $7.50 per share in a primary offering on the Nasdaq Global Select Market under the symbol KYTX. Underwriters have a 30-day option to buy up to an additional 1,999,999 shares at the same price, less underwriting discounts and commissions of $0.45 per share. Gross proceeds are approximately $99.999 million, with estimated net proceeds of about $93.7 million, or $107.8 million if the option is fully exercised.
The company plans to use the cash, together with existing cash and cash equivalents, prior at-the-market sales of $16.9 million and loan proceeds, for general corporate purposes including research and development, capital expenditures, working capital and administrative costs. Management believes this funding will support operations through 2028 and back a planned biologics license application for stiff person syndrome and a Phase 3 trial in generalized myasthenia gravis.
Kyverna is a clinical-stage cell therapy company focused on autoimmune diseases, led by its CD19 CAR T candidate mivocabtagene autoleucel (miv-cel). Recent registrational Phase 2 data in stiff person syndrome showed functional gains, sustained freedom from immunotherapies and no high-grade CRS or ICANS, with Grade 3/4 neutropenia reported in 62% of patients and described as manageable.
Kyverna Therapeutics' chief technology officer reported an option exercise and share sale in Kyverna Therapeutics, Inc. common stock. On 12/15/2025, the officer exercised stock options to acquire 23,998 shares at an exercise price of $4.83 per share and, on the same date, sold 23,998 shares at $12.2 per share. After these transactions, the officer beneficially owned 22,636 shares of common stock directly and held 85,865 stock options.
The filing states that these trades were made under a Rule 10b5-1 trading plan adopted on September 12, 2025, which automates transactions according to preset instructions. The option originally vested 25% of the shares on January 1, 2025, with the remaining portion vesting in equal monthly installments, contingent on continued service.
Kyverna Therapeutics is offering $100,000,000 of common stock, with underwriters holding a 30-day option to buy up to an additional $15.0 million of shares. The clinical-stage company develops CD19 CAR T-cell therapies for autoimmune diseases, led by its autologous candidate mivocabtagene autoleucel (miv-cel). It plans to use net proceeds, together with existing cash, for general corporate purposes including research and development, and states that, combined with prior at-the-market sales and loan proceeds, this financing is expected to fund operations through 2028 and support a planned BLA filing in stiff person syndrome (SPS) and a Phase 3 trial in myasthenia gravis (MG).
Kyverna recently reported positive topline data from the registrational KYSA-8 Phase 2 SPS trial in 26 patients: among 12 patients who needed a walking aid before treatment, 67% no longer required assistance at Week 16; 100% remained off immunotherapies without rescue therapy at last follow-up. Miv-cel was described as well-tolerated, with no high-grade CRS or ICANS and Grade 3/4 neutropenia in 62% of patients, which was reported as manageable and resolved.
Kyverna also highlights a non-dilutive term loan facility of up to $150.0 million with Oxford Finance. It has drawn $25.0 million, and the positive KYSA-8 data made an additional tranche of up to $20.0 million available, bringing currently available undrawn funding to $35.0 million. The company cautions that investing in its stock involves a high degree of risk, including dilution from this offering, potential future equity issuances, broad discretion over proceeds and significant stock price volatility.
Kyverna Therapeutics, Inc. announced positive topline data from KYSA-8, a registrational Phase 2 trial of its fully human, autologous CD19 CAR T-cell therapy mivocabtagene autoleucel (miv-cel, formerly KYV-101) in stiff person syndrome.
The company is hosting a conference call at 8:00 a.m. Eastern Time on December 15, 2025 to review the results and has provided an investor slide presentation as Exhibit 99.1, which is furnished rather than filed under federal securities law provisions.
Kyverna Therapeutics reported positive topline data from KYSA-8, its registrational Phase 2 trial of mivocabtagene autoleucel (miv-cel, formerly KYV-101), a fully human, autologous CD19 CAR T-cell therapy with CD28 co-stimulation, in stiff person syndrome.
The company also stated it will host a conference call at 8:00 a.m. Eastern Time on December 15, 2025 to review the results, and made a detailed press release available describing the KYSA-8 data and its implications for the miv-cel program.
Kyverna Therapeutics (KYTX) filed its Q3 2025 10‑Q. The company reported a net loss of
Liquidity remained solid with cash, cash equivalents and marketable securities of
Management estimates that, with the initial
Kyverna Therapeutics, Inc. (KYTX) furnished an 8-K announcing it issued a press release with a business update and financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information under Item 2.02 and Exhibit 99.1 is furnished, not filed, under the Exchange Act and will not be incorporated by reference into Securities Act or Exchange Act filings unless specifically referenced. The report was signed by Chief Financial Officer Marc Grasso, M.D.
Kyverna Therapeutics (KYTX) entered a non-dilutive term loan facility of up to $150.0 million with Oxford Finance, structured in multiple tranches. The facility includes an initial $40.0 million tranche and two additional tranches totaling $60.0 million, with a discretionary fourth tranche of $50.0 million. The company expects to draw $25.0 million from the first tranche on November 3, 2025.
The loan matures on October 1, 2030 and bears a floating rate equal to the greater of the 1‑Month CME Term SOFR or 3.75%, plus 5.00%. Kyverna will make interest-only payments until November 1, 2028 or, at its option upon meeting certain milestones, until November 1, 2029, after which principal and interest are due monthly. The agreement is secured by substantially all assets, including intellectual property, and includes customary events of default.
The company also announced it now expects to report topline registrational data for its Phase 2 KYV‑101 trial in stiff person syndrome in early 2026.
Kyverna Therapeutics (KYTX)KYV-101 in generalized myasthenia gravis. The company will host a conference call at 8:00 a.m. Eastern Time on October 29, 2025 to review the results.
Slides for the call are furnished as Exhibit 99.1. The information was furnished under Item 7.01 and is not deemed “filed” under the Exchange Act.
FAQ
What is the current stock price of Kyverna Therapeutics (KYTX)?
What is the market cap of Kyverna Therapeutics (KYTX)?
